GLP-1 medications reduce hunger and increase satiety, but they do not eliminate the desire to eat entirely
Instead, focus on eating whole, healthy foods rich in protein, fiber, and healthy fats
PMID: 28831150 Guo XH (2016): The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide
73 ZhangJ.LiX.LengX.ZhangC.HanZ.ZhangF
Schedule a consultation at 5375 S Fort Apache Rd, Suites 102 & 103, Summerlin, Las Vegas, NV 89148, or book a telehealth visit from anywhere in Nevada
Strong medical expertise and pharmaceutical innovation capabilities are supporting the adoption of cutting-edge GLP-1 technologies among healthcare providers prioritizing treatment quality and patient outcomes excellence in diabetes care applications